Advisors Management Group Inc. ADV Has $3.12 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Advisors Management Group Inc. ADV reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,741 shares of the biopharmaceutical company’s stock after selling 393 shares during the period. Advisors Management Group Inc. ADV’s holdings in Gilead Sciences were worth $3,117,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Park Avenue Securities LLC increased its holdings in Gilead Sciences by 31.4% in the 4th quarter. Park Avenue Securities LLC now owns 28,753 shares of the biopharmaceutical company’s stock worth $2,656,000 after purchasing an additional 6,878 shares in the last quarter. Kathmere Capital Management LLC increased its holdings in Gilead Sciences by 42.7% in the fourth quarter. Kathmere Capital Management LLC now owns 17,527 shares of the biopharmaceutical company’s stock worth $1,619,000 after purchasing an additional 5,246 shares in the last quarter. San Luis Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 3.3% during the 4th quarter. San Luis Wealth Advisors LLC now owns 9,885 shares of the biopharmaceutical company’s stock valued at $913,000 after acquiring an additional 319 shares during the period. Accurate Wealth Management LLC grew its stake in shares of Gilead Sciences by 7.1% in the 4th quarter. Accurate Wealth Management LLC now owns 3,456 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 230 shares during the period. Finally, 180 Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 81.1% during the fourth quarter. 180 Wealth Advisors LLC now owns 10,990 shares of the biopharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 4,920 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Piper Sandler lifted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Stock Up 1.5 %

Gilead Sciences stock opened at $92.38 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $115.13 billion, a P/E ratio of 1,026.44, a P/E/G ratio of 2.24 and a beta of 0.18. The stock’s fifty day simple moving average is $91.96 and its 200-day simple moving average is $83.69. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 earnings per share. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock worth $41,902,086 in the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.